Atrial Fibrillation – Epidemiology – Americas Data
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets are forecast over a period of 20 years; in other countries, forecasts are over 10 years. In addition to forecasting prevalent patient populations, we calculate the number of drug-treatment opportunities in specific lines of therapy in the mature pharmaceutical markets.
DRG Epidemiology’s atrial fibrillation forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people living with atrial fibrillation?
Of all people with atrial fibrillation, how many in each country have been formally diagnosed?
Of all people diagnosed with atrial fibrillation, how many in the mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of atrial fibrillation over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the mature pharmaceutical markets. These patient flows are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following atrial fibrillation patient populations:
Diagnosed prevalent cases by symptom frequency.
Diagnosed prevalent cases of atrial fibrillation.
Diagnosed prevalent cases by CHADS2 score.
Diagnosed prevalent cases by comorbid heart failure.
Drug-treated prevalent cases of atrial fibrillation.
Non-drug-treated prevalent cases of atrial fibrillation.
Diagnosed prevalent cases by first detected event.
Diagnosed prevalent cases by comorbid hypertension.
Atrial Fibrillation - Epidemiology - Americas Data
Diagnosed Prevalence of Atrial Fibrillation per 1000 Among People Aged 40+ in 2021 and 2031ttttttttt
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Atrial Fibrillation over the Next 10 yearstttttttt
Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 by Disease Subtypetttttttt
Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Heart Failuretttttttt
Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Hypertensiontttttttt
Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation Across the Countries Under Study in 2021 with Comorbid Valvular Heart Diseasetttttttt
Number of Additional Prevalent Cases of Atrial Fibrillation in 2041 Across the Countries Under Study Due to Trends in Obesitytttttttt
Total Prevalent Cases
Diagnosed Prevalent Cases
Diagnosed Prevalent Cases by Subtype
Comorbid Heart Failure
Comorbid Valvular Heart Disease
Stroke Risk Based on CHADS2 Score
Studies Included in the Analysis of Atrial Fibrillation
Studies Excluded from the Analysis of Atrial Fibrillation
Risk/Protective Factors for Atrial Fibrillation
Utsav Patel, M.P.H.,is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.